Table 1 Demographic, clinical and neuropathological data for the samples included in the study
N | FTLD-Tau | FTLD-TDP | AD | Control | p-value |
|---|---|---|---|---|---|
24 | 25 | 25 | 35 | ||
Female, n (%) | 6 (25) | 13 (52) | 10 (40) | 20 (57) | .08 |
Education (years) | 15.6 (3.5) | 15.1 (2.7) | 14.8 (3.1) | 15.7 (3.4) | .40 |
Age-at-disease onset (years) | 64 (9.3) | 63 (9.0) | 69 (5.6) | NA | .02a |
Age-at-CSF analysis (years) | 67 (11.3) | 66 (8.7) | 73 (5.7) | 69 (7.3) | .04b |
Age-at-death (years) | 71 (12.6) | 70 (9.5) | 79 (6.0) | NA | .005c |
Time interval, onset–CSF (years) | 3.7 (2.7) | 3.7 (2.7) | 3.6 (1.6) | NA | .79 |
Time interval, CSF–death (years) | 4.6 (3.6) | 3.6 (3.0) | 6.0 (2.3) | NA | .01d |
Total disease duration, onset–death (years) | 8.4 (4.5) | 7.2 (3.4) | 9.6 (3.0) | NA | .07 |
Participants without comorbidity, n (%) | 20 (83) | 19 (76) | 18 (72) | NA | .63 |
Global Tau pathology | 29.3 (12.0) | 10.0 (8.0) | NA | NA | < .0001 |
Global TDP pathology | 9.7 (10.1) | 26.1 (6.8) | NA | NA | .0002 |
MMSE score | 24.0 (5.2) | 20.9 (6.8) | NA | NA | .29 |
Time interval, CSF–MMSE (months) | 0.7 (1.2) | 0.7 (0.8) | NA | NA | .84 |